Due to the crucial involvement of the idiotypic network in the autoimmune diseases and the promising therapeutic applications, the detailed model we present for Ab2-AIM2 and for its interaction with Ab1-MB2.8 could be the basis for new possible therapeutic strategies, such as the design of humanized antibodies for the inhibition of TG2 binding by autoantibodies in celiac disease. This evidence concerns the gene AIM2 and celiac disease.